Manifold Raises $18 Million Series B to Define Vertical AI for Life Sciences and Accelerate Life-changing Medicines to Patients

The new funding cements Manifold’s leadership in the $2 trillion life sciences market, powering next-generation AI workflows from early discovery through precision care.

NEWTON, Mass.–(BUSINESS WIRE)–#ArtificialIntelligence–Manifold, the AI platform for life sciences, today announced an $18 million Series B funding round led by Reach Capital, with participation from SilverArc Capital, Industry Ventures, and existing investors TQ Ventures and Calibrate Ventures. The round brings Manifold’s total capital raised to $40 million and positions the company as the emerging category leader in vertical AI for life sciences. Manifold’s platform is transforming how biopharma companies and medical centers accelerate workflows from target identification to clinical development, market access, and precision medicine in the clinic.

Defining Vertical AI for Life Sciences

Vertical AI platforms are transforming productivity in major industries—legal services, financial services, customer experience, and more—with support for domain-specific data, workflows, and governance that go much deeper than horizontal platforms.

In life sciences, a $2 trillion industry where productivity directly impacts patient outcomes, Manifold is defining this category. This field requires purpose-built infrastructure for multi-entity collaboration, multimodal biomedical data, and workflows that span from bench to clinic. Manifold’s platform is purpose-built for this complexity.

“In every industry, companies that combine agentic AI and domain-specific context will transform productivity. Customers are seeking proven partners in this transformation. We believe Manifold is the emerging category leader for vertical AI in life sciences,” said Jennifer Carolan, Partner at Reach Capital.

Accelerating Agent Development and the Data Flywheel

The new funding will enable Manifold to advance its platform with capabilities that materially improve life sciences productivity:

• Expand the Agent OS: Advancing how AI agents operate on multimodal biomedical data, use scientific tools, and leverage institutional context to accelerate work, from biomarker development and model validation through trial design and real-world evidence generation.
• Deepen collaboration infrastructure: Extending features that enable teams to share analyses, reuse context, and work across organizational boundaries with appropriate governance and data sovereignty.
• Scale the data ecosystem: Constructing novel datasets becomes easier as more organizations join, compounding value for all participants while maintaining data ownership and governance.

Strategic Milestones and Growing Momentum

Over the past year, Manifold has achieved significant milestones that demonstrate both strong product-market fit and compounding network effects:

• Workflow breadth: AI agents which can be tailored to specific datasets and tools across dozens of workflows—from cohort identification and biomarker discovery to treatment pathway analysis and outcomes research.
• Enterprise momentum: A growing customer base including leading companies like Foundation Medicine and academic centers like the University of Virginia.
• Strategic collaborations: Deepening strategic collaborations with the Broad Institute, AWS, and Anthropic which strengthen both scientific and technical capabilities and go-to-market reach.
• Terra operation: As an operator of Terra, Manifold now serves thousands of researchers across hundreds of life sciences organizations globally.

“Our customers and partners are pushing the boundaries of what’s possible in life sciences, and we’re honored to build alongside them. This funding accelerates our shared goal to transform productivity in life sciences and get life-changing medicines to patients faster,” said Vinay Seth Mohta, CEO, Manifold.

For an inside look at the vision driving Manifold’s next phase of growth, visit the CEO blog.

About Manifold

Manifold is the AI platform for life sciences, accelerating life-changing medicines to patients. Our products speed up workflows in areas from target identification and clinical development to market access and precision medicine in the clinic, while maintaining the governance life sciences requires. Global companies and premier research institutions use Manifold to operate faster and more effectively. Backed by leading investors including Reach Capital, TQ Ventures, Calibrate Ventures, SilverArc Capital, and Industry Ventures, Manifold serves tens of thousands of users across hundreds of organizations globally.

Contacts

Press
Alec Biedrzycki

VP of Marketing

Manifold AI

press@manifold.ai